More women with ovarian cancer will gain access to olaparib (Lynparza) after its PBS listing is expanded to include first-line maintenance therapy from 1 November. The PARP inhibitor has been available on the PBS since 2017 to women whose BRCA-mutated, stage 3 and 4 platinum sensitive ovarian cancer had relapsed. Under an expended listing it ...
Olaparib PBS listed for first-line maintenance in advanced ovarian cancer
By Michael Woodhead
12 Oct 2020